Introduction
In a previous communication from this centre (Ziegler et al., 1970a ) the neurological features of Burkitt's lymphoma were described. The presence of Burkitt lymphoma cells in the cerebrospinal fluid (malignant pleocytosis) was a prominent finding, and though patients with this complication were initially responsive to intrathecal chemotherapy, relapse was common and the prognosis was poor. In a neoplasm characterized by dramatic and often durable remissions following chemotherapy the successful management of malignant pleocytosis presents a major therapeutic challenge (Clifford et al., 1967; Ziegler et al., 1970a) . We have now treated 55 episodes of malignant pleocytosis in 38 patients with Burkitt's lymphoma utilizing methotrexate and cytosine arabinoside in seven different intrathecal regimens. This report summarizes the results of intrathecal chemotherapy in this group of patients, some of whom have been followed for up to three years. In addition, prophylactic intrathecal chemotherapy was evaluated in a randomized study in 20 patients with Burkitt's lymphoma presenting without malignant pleocytosis.
Patients and Methods
All patients admitted to the Lymphoma Treatment Centre, an 18-bed research ward affiliated with Makerere University Medical School, were referred from Mulago Hospital, Kampala, or from up-country district hospitals in Uganda. On arrival at the centre the patients underwent a careful clinical evaluation which included a complete neurological examination and lumbar puncture. The cerebrospinal fluid (C.S.F.) cytology was examined on admission and at least at monthly intervals, several methods (Steel et al., 1965; Ziegler et al., 1970a) being used to detect the presence of malignant cells. The patients were clinically staged according to criteria previously outlined (Ziegler et al., 1970b) ; these are summarized in Table I .
Previous to August 1969 systemic treatment consisted of intravenous cyclophosphamide, 40 mg/kg, given in one-dose or six-dose schedules (multiple doses given at intervals of two to three weeks) to randomly selected patients who had a complete response following the first dose (Ziegler et al., 1970b) . After Central nervous system (malignant cells in the C.S.F.) or bone marrow involvement the conclusion of this trial, in which multiple doses emerged as the treatment of choice for patients without localized tumours -that is stages III and IV-patients were randomized to six doses of cyclophosphamide versus a sequential regimen consisting of cyclophosphamide (40 mg/kg, intravenously) followed in two weeks by vincristine (1 4 mg/M2 intravenously) and methotrexate (15 mg/M2 by mouth for four days starting the same day as the vincristine administration), followed in two weeks by cystine arabinoside (250 mg/M2 in a daily infusion for three days). The latter sequence was repeated for a total of two cycles. With few exceptions, all patients with malignant pleocytosis were treated systemically with one of the above regimens at the same time that intrathecal chemotherapy was administered.
The different intrathecal chemotherapeutic regimens in the order in which they were used since August 1967 are shown in Table II . A total of 55 episodes of malignant pleocytosis were treated in 38 patients. All patients but two were in the age range of 3 to 14 years. Methotrexate and cytosine arabinoside, diluted in 3 ml of sterile isotonic saline, were instilled with several exchanges of C.S.F. in the syringe. Those receiving methotrexate also had milligramme-equivalent doses of intramuscular citrovorum factor (calcium leucovorin) in six-hourly divided doses over 24 hours and begun at the time of each intrathecal instillation.
All patients with Burkitt's lymphoma presenting between August 1969 and July 1970 who did not have malignant pleocytosis on admission (stages [-l1) were randomly allocated to receive either "prophylactic" intrathecal chemotherapy or no intrathecal chemotherapy. The regimen used in patients designated to receive treatment was the four-day alternating schedule of methotrexate and cytosine arabinoside (Table Il) ; two doses of each drug were administered. All randomized patients were subsequently followed with serial lumbar punctures at intervals of two to four weeks.
Results
The results of each intrathecal chemotherapeutic trial are summarized in Table II . All patients but two had complete disappearance of Burkitt lymphoma cells from the C.S.F. within one week following one course of any therapeutic regimen. The two patients who failed to respond compleely showed a pronounced reduction but not complete disappearance of malignant pleocytosis following intrathecal chemotherapy. The relapse rate with each regimen was high, however, varying from 60 to 100% (Table II) . The mean time to relapse was less than 17 weeks in all instances. Though relapse is defined as the reappearance of Burkitt lymphoma cells in the C.S.F., several 509 patients were noted to relapse with only one to five malignant cells which persisted in the absence of intrathecal therapy for as long as 20 weeks without increasing in number.
It was previously reported that two out of five patients receiving weekly intrathecal methotrexate early in the study achieved long-term C.S.F. remissions (Ziegler et al., 1970a) . These patients were still alive and well 144+ and 156+ weeks after therapy. The remaining three patients relapsed with malignant pleocytosis, and subsequent intrathecal therapy with cytosine arabinoside yielded complete, though transient, responses. A subsequent trial using both agents alternately at four-day intervals was evaluated in 15 previously untreated patients; all 13 complete responders eventually relapsed at a median of 10-1 weeks (Ziegler et al., 1970a) .
The next trial consisted of methotrexate 15 mg (with citrovorum) given daily for four days to 11 patients, seven of whom had relapsed from the methotrexate and cytosine arabinoside alternate regimen. Eight patients relapsed with a mean remission duration of 16-8 weeks, and the remaining three were well 28±, 39+, and 48+ weeks from therapy.
Six patients relapsing from four-day intrathecal methotrexate and a seventh previously untreated patient were treated with intrathecal cytosine arabinoside, 30 mg daily for four days. Five relapsed on this regimen, with a mean remission duration of 14-4 weeks, and two were still in C.S.F. remission at 9+ and 36+ weeks.
Of the total of 18 patients receiving the four-day regimen, five (four receiving methotrexate and one receiving cytosine arabinoside) had not had previous intrathecal chemotherapy. The relapse rate or C.S.F. remission duration of these five patients was not different from the remainder of patients not previously treated.
In a more aggressive attempt to eradicate malignant cells from the C.S.F. a 10-day schedule of intrathecal methotrexate (with citrovorum) was then instituted. Seven of nine evaluable patients relapsed within four weeks from the completion of therapy (Table II) . Five patients previously treated with four-day intrathecal chemotherapy (one receiving methotrexate and four receiving cytosine arabinoside) were not different with respect to relapse rate or remission duration from previously untreated patients.
In a subsequent trial five patients were treated with intrathecal cytosine arabinoside 30 mg, given daily for 10 days. All patients had complete C.S.F. responses, but three relapsed at four, four, and five weeks respectively (Table II) , two of whom were previously untreated. The remaining two were well 13+ and 15 + weeks from therapy.
A comparison of the C.S.F. remission duration (life table analysis) observed in patients treated with either four-day or 10-day methotrexate is shown in Fig. 1 , and a similar comparison of patients receiving cytosine arabinoside (four-day versus 10-day) is shown in Fig. 2 . In the patients receiving methotrexate longer remissions were achieved with the four-day regimen. Both groups were comparable, with regard to other clinical variables, including the proportion of patients previously untreated with intrathecal agents. Though the number of patients receiving cytosine arabinoside was small, the remission durations were also longer in those receiving the four-day regimen compared with the 10-day course. (4-27) ARA-C 10-50 mg weekly .. In this prospective study group three patients (one from the treatment group and two from controls) developed only one tumour cell in the C.S.F. This finding was unequivocally confirmed by several observers with a large experience in the cytology of Burkitt's lymphoma. These patients, otherwise in complete remission, have been followed for many weeks without therapy and during this time no increase in C.S.F. cell count has been noted.
Central nervous system involvement is a prominent clinical feature in patients with Burkitt's lymphoma, and malignant pleocytosis, encountered in 45% of our patients during the past three years, constitutes our most difficult problem in therapeutic management. In a neoplasm potentially "curable" by chemotherapy a rational and effective approach to the treatment of malignant pleocytosis is critically needed (Ziegler et al., 1970a (Ziegler et al., , 1970b . The pathogenesis of malignant pleocytosis, the kinetics of tumour cells in the C.S.F., and the pharmacology of the cytotoxic agents used are important considerations in this regard.
From recent clinical and pathological studies it appears that Burkitt tumour cells may gain access to the subarachnoid space by direct extension from involved facial bones, cranial or peripheral nerves, or other extradural sites (Clifford et al., 1967; Frank, 1968; Ziegler et al., 1970a) . It is possible that tumour cells initially find sanctuary in these extradural sites (particularly perineurium or periosteum) from the effects of systematic cytotoxic agents and subsequently migrate direct to the subarachnoid space much in the manner shown in experimental leukemia in mice (Thomas, 1965 (Ziegler et al., 1970a (Iversen et al., 1971) . If tumour cells in the C.S.F. behave similarly, adequate C.S.F. levels of cycle-active agents such as methotrexate and cytosine arabinoside should be maintained over a period of several doubling times-that is, at least four days-in order to achieve a maximum cytotoxic effect.
The pharmacodynamics of the blood-brain barrier has been reviewed by Rall (1965 (Clifford et al., 1967) .
Intrathecal chemotherapy and irradiation of the central nervous system has been effective in the treatment of malignant pleocytosis, and a substantial experience with methotrexate and cytosine arabinoside has been gained in the treatment of meningeal leukaemia. A high percentage of initial complete responses has been reported, but relapse is almost always encountered (Sullivan et al., 1969) . The pharmacology of methotrexate administered intrathecally is well characterized This observation could be explained (in patients receiving methotrexate) by postulating a tumour-enhancing effect of prolonged administration of citrovorum factor on tumour cells outside the subarachnoid space which were "'seeding" the C.S.F. Alternatively, new tumour cells may have been introduced into the C.S.F. by multiple lumbar punctures, though there was no gross or radiological evidence in any of the patients of paraspinal tumour in the path of the spinal needle. It is also possible that prolonged methotrexate administration arrested the cell cycle outside the S phase with accumulation of cells in Gi, which rapidly regained proliferative potential once the drug was stopped (0. S. Selawry and C. G. Zubrod, personal communication). Finally, drug resistance could have developed, though the high concentrations of drug in the C.S.F. should overcome this event (Reiselbach et al., 1963) .
Intrathecal cytosine arabinoside appears to be a useful treatment for malignant pleocytosis in Burkitt's lymphoma, and no substantial differences in complete remissions, relapse rate, or remission duration were detected in comparing patients receiving four-day methotrexate with four-day cytosine arabinoside. Further trials of cytosine arabinoside as initial intrathecal therapy will be necessary, as most of the patients treated with this agent had already received previous intrathecal chemotherapy.
MALIGNANT CELLS IN C.S.F.
One important feature which has emerged from these investigations is the achievement in several patients of long-term C.S.F. remissions, indicating the possibility of eradicating malignant cells from the C.S.F. for long periods of time.
Another small group of patients developed very low numbers of malignant cells in the C.S.F. for prolonged periods following 511 intrathecal or systemic chemotherapy. Some of these patients eventually develop significant malignant pleocytosis, whereas others are found to have persistently low C.S.F. malignant cell counts. Our initial therapeutic policy was to administer intrathecal chemotherapy to all patients with even one Burkitt lymphoma cell in the C.S.F., but more recently we have been following patients with "indolent" malignant pleocytosis with periodic C.S.F. surveillance. Continued observation will be necessary to determine the clinical significance of this finding. Careful scrutiny of these patients has thus far failed to indicate any predictive or distinctive features. A randomized trial of prophylactic intrathecal chemotherapy in patients without malignant pleocytosis on admission showed no protective effect against the subsequent development of this complication. This observation implies that tumour cells migrated to the subarachnoid space after initial therapy and were not occultly present in the C.S.F. on admission. The appearance of a simultaneous "systemic" tumour relapse in two of the five treated patients developing malignant pleocytosis supports this concept. Careful surveillance of the C.S.F. in all patients with Burkitt's lymphoma throughout their clinical course is therefore mandatory, and prompt institution of both intrathecal and systemic chemotherapy is indicated when significant malignant pleocytosis is observed.
The results of this study may have important implications for the management of patients with meningeal leukaemia. This complication often develops when the patient is otherwise in complete bone marrow remission. In these patients it may be important to begin systemic induction chemotherapy at the time of meningeal relapse, even though malignant pleocytosis is the only manifestation of disease. Neuropathological evidence indicates that dural deposits are not responsive to intrathecal chemotherapy, whereas arachnoid infiltrations will regress (Wang and Pratt, 1970) . Leukaemic cells residing in the meninges but not accessible to intrathecal chemotherapy may thus be reached by cytotoxic agents. The optimum schedule of intrathecal administration is not known, but daily administration for at least four days in a dose and schedule similar to the present study may be useful.
The therapeutic effect of intrathecal administration of a large volume of drug has not been clinically evaluated, but is of obvious anatomical significance with regard to distribution of drug . The use of the Ommaya reservoir for ventricular perfusion provides a convenient route of administration of intrathecal agents, and may improve drug distribution within the subarachnoid space (Rubin et al., 1966 and 16 weeks respectively. Five patients received cytosine arabinoside and C.S.F. relapse occurred at 3, 3, 3, 4, and 14 weeks respectively. Thus in this small trial neither agent appears to be superior with regard to remission duration, and the larger volume of diluent did not seem to favourably affect the outcome of these patients compared with our previous experience using a small volume of diluent. Introduction A fall of oxygen tension in stored blood samples due to metabolism is well recognized. Reports of additional changes in oxygen tension in both blood and water samples stored in plastic syringes are conflicting (Laver and Seifen, 1965; Fletcher and Barber, 1966; Adams et al., 1967) , but the work of Hilty and Karendal (1969) Nielsen, 1961; Hedley-White and Laver, 1964) . All experiments were performed by one investigator.
The fall in oxygen tension in water during storage in six different brands of 5-ml plastic syringe and one 5-ml glass syringe is shown in Fig. 1 . The water was initially in equilibrium with 96% 0, and, for comparison with other experiments, the fall in tension is expressed as a percentage of the difference between the initial tension in the water and the oxygen tension in the ambient air. Clearly the fall is considerable for all the plastic syringes and small for the glass syringe.
